Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.63 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | BLK | P51451 | 1/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327348 | 0.91 | CHEK1 (0.63) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208014 | 0.89 | CHEK1 (0.81) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL23327238 | 0.86 | CHEK1 (0.69) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL23327145 | 0.84 | CHEK1 (0.63) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL23327139 | 0.82 | CHEK1 (0.63) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL23327140 | 0.81 | CHEK1 (0.62) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL23327315 | 0.80 | CHEK1 (0.82) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208018 | 0.80 | CHEK1 (0.82) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL23327142 | 0.79 | CHEK1 (0.51) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL23327150 | 0.79 | CHEK1 (0.67) | CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11116767-B2 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications | PHARMAENGINE, INC. (TW) | 2021-09-14 | — | — | US | claimed |
| US-20210137918-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE, INC. (TW) | 2021-05-13 | — | — | US | claimed |
| EP-3411036-B1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE INC (TW) | 2021-12-29 | — | — | EP | disclosed |
| US-11116767-B2 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications | PHARMAENGINE, INC. (TW) | 2021-09-14 | — | — | US | disclosed |
| US-20210137918-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE, INC. (TW) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137918-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | CHEK1, CHEK2, BUB1 | CHEK1 1/4885KCNH2 2305/4885NUAK1 137/4885 |
| US-11116767-B2 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications | CHEK1, CHEK2, BUB1 | CHEK1 1/4885KCNH2 2305/4885NUAK1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.